Observing the effects of kratom products on regular users
Official title: Observing the Acute Effects Following a Single Oral Dose of Kratom and Effects Following Kratom Cessation Among Adults Who Use Regularly.
Run by Johns Hopkins University · NCT06089980 · Data updated 2026-11-12
This study looks at how regular users of kratom feel and function after taking their usual dose, while also checking what happens when they stop using it.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 22 (estimated) |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Status | Recruiting |
| Started | April 1, 2024 |
| Main results expected | February 2028 |
| Study ends | February 2028 |
| Registry record updated | January 23, 2026 |
| Trial ID | NCT06089980 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 21 who have been using kratom more than five times a week for at least three months.
✕Probably not a fit
Patients who have experienced acute adverse health events related to kratom use or have current dependencies on certain substances may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the effects of commercial kratom products on healthy adults who consume them regularly. Participants will self-administer a single oral dose of their usual kratom product, and the study will assess the acute physiological, subjective, and cognitive effects of this dose. Additionally, the study will explore the effects of kratom product discontinuation and analyze the pharmacokinetics of kratom in regular users through blood draws and urine collection. The goal is to gather comprehensive data on how kratom affects users in real-time.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the safety and effects of kratom, potentially guiding better usage practices for consumers.
How similar studies have gone: While there is limited research specifically on kratom, studies on similar herbal products have shown varying degrees of success in understanding their effects.
Who can join: the full rules
Show full inclusion / exclusion criteria
INCLUSION CRITERIA: 1. \>21 years 2. reporting kratom use \>5 times per week for \>3 months prior to study screening 3. English language proficiency 4. Willingness to provide requested samples of the kratom product being currently taken EXCLUSION CRITERIA: 1. Reports any acute adverse, unexpected, or otherwise sudden health event related to the typical kratom product dose that occurred within 30 days of screening 2. Having ever sought medical attention for an acute adverse health event as a result of taking any kratom product. 3. Cannot or will not provide kratom product samples in the form of an unopened package of kratom that is clearly labeled with at least the product and vendor name. 4. Self-reports using kratom products by any other route than orally swallowing. 5. Current physical dependence on alcohol, benzodiazepines, or opioids 6. Reports use of fentanyl within the past month and/or has a fentanyl positive drug screen. 7. Discordance between self-reported substance use and drug screen results obtained during screening. 8. Lifetime or current psychotic disorder 9. Current untreated major depressive or bipolar disorder 10. Pregnancy or nursing 11. Physical, psychiatric, or environmental conditions considered by study team to increase risk or undue burden (e.g., untreated hypertension, high BMI, etc.).
Where it's running
-
Johns Hopkins University
Baltimore, Maryland, United States Recruiting
Study contacts
- Principal investigator: Kirsten E Smith, Ph.D. — Johns Hopkins University
- Study coordinator: Kirsten E Smith, Ph.D.
- Email: ksmit398@jh.edu
- Phone: 865-418-8177
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Psilocybin-assisted therapy to help adults with amblyopia see more clearly
This study tests whether a single or small doses of psilocybin can boost the effectiveness of amblyopia treatment in adults.
-
ReVIVE for mTBI: Using VR and therapy to help adults with mild traumatic brain injury
This study tests a virtual reality therapy combined with standard psychotherapy to see if it can reduce PTSD symptoms and improve executive function in adults with mild traumatic brain injury.
-
Social Connection Collective for older adults in subsidized housing
A resident-led program in subsidized housing in Baltimore will try to build friendships and peer support among residents aged 62 and older to see if it’s feasible and if it reduces loneliness.
-
Oral Food Challenge After Starting Omalizumab in Food Allergy
This trial tests whether omalizumab begins to help with food allergy within 2 to 4 weeks after starting treatment in people with a confirmed food allergy.
-
Imaging markers for bulbar involvement in inclusion body myositis among IBM and comparison groups
This study tests whether ultrasound and MRI can detect swallowing and bulbar muscle problems in people with inclusion body myositis.
-
Impact of Patient Position on EndoFLIP Measurements in Kids and Young Adults
This study tests whether EndoFLIP measurements differ when patients are in the supine versus left-side position during the procedure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.